JP7303182B2 - 糖尿病関連用途のための方法及び抗体 - Google Patents

糖尿病関連用途のための方法及び抗体 Download PDF

Info

Publication number
JP7303182B2
JP7303182B2 JP2020507985A JP2020507985A JP7303182B2 JP 7303182 B2 JP7303182 B2 JP 7303182B2 JP 2020507985 A JP2020507985 A JP 2020507985A JP 2020507985 A JP2020507985 A JP 2020507985A JP 7303182 B2 JP7303182 B2 JP 7303182B2
Authority
JP
Japan
Prior art keywords
antibody
antibodies
amino acid
gcd59
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020507985A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020517306A (ja
JP2020517306A5 (https=
Inventor
チョレフ、マイケル
エイ． ハルパリン、ホセ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mellitus LLC
Original Assignee
Mellitus LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mellitus LLC filed Critical Mellitus LLC
Publication of JP2020517306A publication Critical patent/JP2020517306A/ja
Publication of JP2020517306A5 publication Critical patent/JP2020517306A5/ja
Priority to JP2023024232A priority Critical patent/JP2023078133A/ja
Application granted granted Critical
Publication of JP7303182B2 publication Critical patent/JP7303182B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2020507985A 2017-04-21 2018-04-17 糖尿病関連用途のための方法及び抗体 Active JP7303182B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023024232A JP2023078133A (ja) 2017-04-21 2023-02-20 糖尿病関連用途のための方法及び抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762488346P 2017-04-21 2017-04-21
US62/488,346 2017-04-21
PCT/US2018/027856 WO2018195008A1 (en) 2017-04-21 2018-04-17 Methods and antibodies for diabetes-related applications

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023024232A Division JP2023078133A (ja) 2017-04-21 2023-02-20 糖尿病関連用途のための方法及び抗体

Publications (3)

Publication Number Publication Date
JP2020517306A JP2020517306A (ja) 2020-06-18
JP2020517306A5 JP2020517306A5 (https=) 2021-05-27
JP7303182B2 true JP7303182B2 (ja) 2023-07-04

Family

ID=63856388

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020507985A Active JP7303182B2 (ja) 2017-04-21 2018-04-17 糖尿病関連用途のための方法及び抗体
JP2023024232A Pending JP2023078133A (ja) 2017-04-21 2023-02-20 糖尿病関連用途のための方法及び抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023024232A Pending JP2023078133A (ja) 2017-04-21 2023-02-20 糖尿病関連用途のための方法及び抗体

Country Status (7)

Country Link
US (1) US11866506B2 (https=)
EP (1) EP3612625A4 (https=)
JP (2) JP7303182B2 (https=)
AU (1) AU2018255244A1 (https=)
SG (1) SG11201909708VA (https=)
TW (1) TW201902927A (https=)
WO (1) WO2018195008A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201909708VA (en) 2017-04-21 2019-11-28 Mellitus Llc Methods and antibodies for diabetes-related applications
CN112924682B (zh) * 2019-12-05 2023-02-10 张曼 尿液纤维蛋白原α链蛋白及其多肽片段在正常妊娠中的应用
US11303968B1 (en) 2020-10-09 2022-04-12 Hulu, LLC Personalized ranking of entities in an electronic programming guide for live television
CN112904009B (zh) * 2021-02-19 2022-03-18 山东莱博生物科技有限公司 一种检测糖基化cd59的磁性微球检测试剂盒及其应用
WO2022241236A2 (en) * 2021-05-13 2022-11-17 Mellitus, Llc Methods and reagents for protein analysis
CN115290609B (zh) * 2021-12-22 2024-08-09 温州医科大学 快速检测肝素的试剂及检测方法
CN115144348B (zh) * 2022-07-06 2025-02-14 浙江伊利康生物技术有限公司 糖化白蛋白检测试剂盒、制备方法及其应用方法
WO2024166110A1 (en) * 2023-02-12 2024-08-15 Hadasit Medical Research Services And Development Ltd. Targeted reduction of cd59 for use in treating disease
WO2024254501A1 (en) * 2023-06-07 2024-12-12 Dexcom, Inc. Systems and methods for diabetes prediction
JP2025026011A (ja) 2023-08-10 2025-02-21 株式会社ツジデン 光集光補助フィルム、該光集光補助フィルムを搭載するエッジライト型バックライトユニット、及び該エッジライト型バックライトを搭載する液晶表示装置。

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017502267A (ja) 2013-12-03 2017-01-19 プレジデント アンド フェローズ オブ ハーバード カレッジ 妊娠性糖尿病の評価のための方法および試薬

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4208479A (en) 1977-07-14 1980-06-17 Syva Company Label modified immunoassays
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
FR2619568B1 (fr) 1987-08-21 1989-07-07 Centre Nat Rech Scient Polymeres derives du polystyrene, leurs procedes de preparation et leurs applications pour l'analyse et la purification de molecules d'origine biologique
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
GB9110962D0 (en) 1991-05-21 1991-07-10 Ici Plc Process
DE69232137T2 (de) 1991-11-25 2002-05-29 Enzon Inc Multivalente antigen-bindende proteine
ES2149768T3 (es) 1992-03-25 2000-11-16 Immunogen Inc Conjugados de agentes enlazantes de celulas derivados de cc-1065.
AU670108B2 (en) 1992-09-11 1996-07-04 Becton Dickinson & Company Improved antibodies to plasmodium falciparum
US5670377A (en) 1996-03-14 1997-09-23 Sansum Medical Research Foundation Method of diagnosing gestational diabetes
US6348584B1 (en) 1996-10-17 2002-02-19 John Edward Hodgson Fibronectin binding protein compounds
EP1958962A3 (en) 1997-06-12 2013-05-01 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
US7439330B2 (en) * 2000-05-08 2008-10-21 President And Fellows Of Harvard College Anti-glycated CD59 antibodies and uses thereof
US6835545B2 (en) 2000-05-08 2004-12-28 President And Fellows Of Harvard College Methods, products and treatments for diabetes
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
GB0124317D0 (en) 2001-10-10 2001-11-28 Celltech R&D Ltd Biological products
US7460960B2 (en) 2002-05-10 2008-12-02 Epitome Biosystems, Inc. Proteome epitope tags and methods of use thereof in protein modification analysis
EP2292259A3 (en) 2002-11-15 2011-03-23 MUSC Foundation For Research Development Complement receptor 2 targeted complement modulators
JP4902961B2 (ja) 2002-12-23 2012-03-21 シェーリング コーポレイション 哺乳動物サイトカインの用途；関連試薬
GB2409456B (en) 2003-10-30 2006-01-04 Proimmune Ltd Oligomeric receptor ligand pair member complexes
CA2612303C (en) 2004-06-17 2018-03-13 Jose Halperin Anti-glycated cd59 antibodies and uses thereof
KR101699142B1 (ko) 2004-06-18 2017-01-23 암브룩스, 인코포레이티드 신규 항원-결합 폴리펩티드 및 이의 용도
US7833725B2 (en) 2005-01-06 2010-11-16 President And Fellows Of Harvard College Mass spectrometric methods and products
US7906625B2 (en) 2005-01-24 2011-03-15 Amgen Inc. Humanized anti-amyloid antibody
CA2606018A1 (en) 2005-04-28 2006-11-02 Ventana Medical Systems, Inc. Nanoparticle conjugates
JP2009515552A (ja) 2005-11-17 2009-04-16 ミレニアム・ファーマシューティカルズ・インコーポレイテッド α４β７インテグリン反応性ヒト化免疫グロブリン
WO2007123708A2 (en) 2006-03-31 2007-11-01 Epitome Biosystems, Inc. Post translational modification pattern analysis
WO2007133623A2 (en) 2006-05-10 2007-11-22 Biopeptides Corporation Peptide diagnostic agent for lyme disease
WO2008058127A2 (en) 2006-11-09 2008-05-15 Irm Llc Agonist trkb antibodies and uses thereof
WO2008137165A1 (en) 2007-05-07 2008-11-13 President And Fellows Of Harvard College Anti-glycated cd59 antibodies and uses thereof
JPWO2009051220A1 (ja) * 2007-10-19 2011-03-03 イムナス・ファーマ株式会社 Ａβオリゴマーに特異的に結合する抗体およびその利用
UA104132C2 (en) 2007-11-13 2014-01-10 Тева Биофармасьютикалз Юесей, Инк. Humanized antibodies against tl1a
US9527924B2 (en) 2010-06-02 2016-12-27 Dana-Farber Cancer Institute, Inc. Humanized monoclonal antibodies and methods of use
WO2012027555A2 (en) 2010-08-25 2012-03-01 President And Fellows Of Harvard College Glycated cd59 peptides, their preparation, and uses thereof
WO2012109538A2 (en) 2011-02-10 2012-08-16 President And Fellows Of Harvard College Surrogates of post-translationally modified proteins and uses thereof
EP2543679A1 (en) 2011-07-08 2013-01-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies for the treatment and prevention of thrombosis
US20140322723A1 (en) 2011-11-22 2014-10-30 President and Dellows of Harvard College Diabetes diagnosis through the detection of glycated proteins in urine
US20150284455A1 (en) 2012-11-06 2015-10-08 Scholar Rock, Inc. Compositions and methods for modulating cell signaling
CN105102480B (zh) * 2012-12-24 2019-04-16 艾伯维公司 催乳素受体结合蛋白及其用途
SG11201909708VA (en) 2017-04-21 2019-11-28 Mellitus Llc Methods and antibodies for diabetes-related applications

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017502267A (ja) 2013-12-03 2017-01-19 プレジデント アンド フェローズ オブ ハーバード カレッジ 妊娠性糖尿病の評価のための方法および試薬

Also Published As

Publication number Publication date
JP2020517306A (ja) 2020-06-18
AU2018255244A1 (en) 2019-10-31
TW201902927A (zh) 2019-01-16
US11866506B2 (en) 2024-01-09
EP3612625A1 (en) 2020-02-26
US20210284751A1 (en) 2021-09-16
SG11201909708VA (en) 2019-11-28
WO2018195008A1 (en) 2018-10-25
EP3612625A4 (en) 2021-08-18
JP2023078133A (ja) 2023-06-06

Similar Documents

Publication Publication Date Title
JP7303182B2 (ja) 糖尿病関連用途のための方法及び抗体
JP6542219B2 (ja) 妊娠性糖尿病の評価のための方法および試薬
CN102037359B (zh) 吞噬细胞的功能评价方法
US20190315846A1 (en) Antibodies to Human Alpha-Synuclein
EP0840126B1 (en) Marker and immunological reagent for dialysis-related amyloidosis, diabetes mellitus and diabetes mellitus complications
TW201925241A (zh) 用於監測對免疫檢查點抑制劑ｐｄ－１和ｐｄ－ｌ１的抗體治療的免疫測定法和基因工程蛋白
US20200271647A1 (en) Biomarkers for predicting prognosis of kidney disease
Mikami et al. Associations between the levels of soluble (pro) renin receptor in maternal and umbilical cord blood and hypertensive disorder of pregnancy
AU2010280368A1 (en) Novel proteins
Stinghen et al. Specific immunoassays for placental alkaline phosphatase as a tumor marker
WO2022241236A2 (en) Methods and reagents for protein analysis
WO2018020477A1 (en) Methods and compositions for treating hypertriglyceridemia
WO1995029692A1 (en) An advanced glycosylation endproduct-receptor, and diagnostic and therapeutic methods based thereon
WO2023225178A1 (en) Methods and reagents for the assessment of gestational diabetes
CN114867745A (zh) Asic1通道拮抗剂抗体
JPH06324046A (ja) 悪性腫瘍の検出方法及びキット
ES2626491B1 (es) Anticuerpos monoclonales frente a bambi y uso para tratamiento de enfermedades inflamatorias
US20160326251A1 (en) Therapeutic agent for cancer, and method for determining prognosis of cancer
HK1229004B (en) Methods and reagents for the assessment of gestational diabetes
HK1229004A1 (en) Methods and reagents for the assessment of gestational diabetes
JP2007332122A (ja) 抗ｎｃ１モノクローナル抗体反応性ペプチド

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210416

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210416

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220215

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220222

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220520

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220715

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20221018

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230220

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20230220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230220

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230313

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20230314

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230523

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230622

R150 Certificate of patent or registration of utility model

Ref document number: 7303182

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150